The Blology of Prostate Cancer (BPC) Program at the Kimmel Cancer Center (KCC) is a new program that emanated from the former Endocrine Mechanisms and Hormone Action in Cancer (EMHAC) Program, and represents the section of the EHMAC that focused on prostate cancer. From 2007 to 2011, EMHAC increased the number of highly productive investigators studying either breast/gynecological malignancies or prostate/genitourinary cancers, allow^ing the strategic creation of the BPC program in 2011. During this same interval, the Greater Philadelphia Prostate Cancer Working Group was founded by new recruit Dr. Karen Knudsen, and served as a basis for development of the BPC and the associated consortium. The BPC program consists of 18 investigators from 10 departments and 3 institutions. The Program currently brings in $2.3 million/year in total costs from NCI grants and $4.1 million/year total peer-reviewed costs. Since 2007, the program produced 343 publications of which, 10% of publications were intra-programmatic, 43% were inter-programmatic, and 5% were both inter- and intra-programmatic. Dr. Karen E. Knudsen (Leader) is an accomplished investigator with expertise in basic and translational prostate cancer research. Dr. Gomella, the Co-Leader (TJU) of BPC, provides clinical expertise in genitourinary malignancies. Dr. Fatatis the Co-leader (Drexel University) of BPC is an accomplished physician scientist with expertise in cancer metastasis at the basic and clinical level. He will play a pivotal role integrating Drexel University and TJU cancer researchers in the BPC Program. The goals of the BPC program are to leverage the significant translational and clinical expertise in genitourinary oncology (most especially with regard to prostate cancer) with the intent to: delineate the mechanisms that underpin prostate cancer development and progression, identify novel means to treat advanced disease, and improve disease management by translating these findings into clinical trials. Studies within the program are directed at developing new strategies for effective detection,diagnosis,and cure.
Specific aims of this program are to;1. Develop new strategies for prevention, detection, and subtyping of early stage prostate malignancies;2. Define the impact of hormone action in malignant disease development and prostate cancer progression;3. Develop novel treatment strategies for prostate malignancies;4. Develop predictive markers for rational therapy delivery.

Public Health Relevance

Prostate cancer remains the most frequently diagnosed malignancy and second leading cause of male cancer death in the United States. Dedicated to eradicating death and suffering from prostate cancer, the Biology of Prostate Cancer (BPC) program combines expert basic and clinical scientists who focus their studies on improving eariy detection and cancer prevention, and on uncovering new effective treatment of advanced disease.

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
5P30CA056036-15
Application #
8753658
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Type
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Ozaki, Shinji; Vuyyuru, Raja; Kageyama, Ken et al. (2016) Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization. Am J Pathol 186:43-56
Teh, Jessica L F; Purwin, Timothy J; Greenawalt, Evan J et al. (2016) An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma. Cancer Res 76:5455-66
Zhao, Yongtong; Shapiro, Sandor S; Eto, Masumi (2016) F-actin clustering and cell dysmotility induced by the pathological W148R missense mutation of filamin B at the actin-binding domain. Am J Physiol Cell Physiol 310:C89-98
Lu, Huimin; Wang, Tao; Li, Jing et al. (2016) αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor. Cancer Res 76:5163-74
Hutcheson, Jack; Balaji, Uthra; Porembka, Matthew R et al. (2016) Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease. Clin Cancer Res 22:3606-17
Singh, Amrita; Fedele, Carmine; Lu, Huimin et al. (2016) Exosome-mediated Transfer of αvβ3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype. Mol Cancer Res 14:1136-1146
Zhao, Qian; Deng, Shengqiong; Wang, Guangxue et al. (2016) A direct quantification method for measuring plasma MicroRNAs identified potential biomarkers for detecting metastatic breast cancer. Oncotarget 7:21865-74
Pattison, Amanda M; Blomain, Erik S; Merlino, Dante J et al. (2016) Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins. Infect Immun 84:3083-91
Curry, Joseph M; Tassone, Patrick; Cotzia, Paolo et al. (2016) Multicompartment metabolism in papillary thyroid cancer. Laryngoscope 126:2410-8
Dowling, John P; Cai, Yubo; Bertin, John et al. (2016) Kinase-independent function of RIP1, critical for mature T-cell survival and proliferation. Cell Death Dis 7:e2379

Showing the most recent 10 out of 674 publications